FDA Recall Bupivacaine Hydrochloride And Epinephrine

View Recall Number, Date, Reasons, Quantity

FDA Recall Enforcement Reports

The most recent Recall Enforcement Report that covers this product was initiated on April 13th, 2022 and classified as a Class II recall due to cgmp deviations: temperature abuse This recall is currently terminated, and the associated recall number is recall number is D-1095-2022. It pertains to Bupivacaine Hydrochloride And Epinephrine identified by 0409-9042 as of 11-30-2023 .

Recall Number Recall Initiation Date Report Date Quantity Product Description Recall Reason Status
D-1095-202204-13-202206-15-202230 vialsBupivacaine Hydrochloride, USP 0.5% (5mg/mL), 25 vials x 50 mL per box, Rx only, MFG: Pfizer, NDC 0409-1163-01cGMP deviations: Temperature abuseTerminated
D-0626-202105-03-202106-09-2021163,957 vials0.5% Bupivacaine Hydrochloride Injection, USP, 150 mg/30 mL (5 mg/mL), 30 mL Single-dose Teartop Vials (NDC 0409-1162-19), packaged in 25 vials per tray (NDC 0409-1162-02), Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA.Labeling: Label Mix-Up: some vials labeled to contain 0.5% Bupivacaine Hydrochloride Injection, USP may contain 1% Lidocaine HCl Injection, USP and some vials labeled to contain 1% Lidocaine HCl Injection, USP may contain 0.5% Bupivacaine Hydrochloride Injection, USPTerminated
D-0218-201708-04-201612-28-2016143,250 vialsBupivacaine Hydrochloride Inj., USP (2.5 mg/mL) 0.25%, packaged in 30 mL Single-dose Preservative-Free vials, Rx Only, Hospira, Inc., Lake Forest, IL 60045, NDC 0409-1159-02Presence of particulate matter: Confirmed customer report for the presence of particulate matter within a single vial.Ongoing
D-1216-201504-23-201507-15-2015150,950 VialsBupivacaine Hydrochloride Inj., USP, 0.5% (5 mg/mL), Preservative-Free, 30 mL Single Use Vials, Rx only. HOSPIRA, INC., LAKE FOREST, IL 60045 USA. NDC: 0409-1162-02.Presence of Particulate Matter: Presence of free-floating and embedded iron oxide particles.Terminated
D-1588-201409-04-201409-24-201475,000 vialsBupivacaine HCl Inj., USP, 0.5% (5 mg/mL), 30 mL Single-dose Preservative-Free, For Nerve Block, Caudal, and Epidural Anesthesia, Not for Spinal Anesthesia, Rx Only, Hospira, Inc., Lake Forest, IL 60045 USA, NDC 0409-1162-02Presence of Particulate Matter: A confirmed customer complaint reported the presence of a brown, rust-colored particle embedded at the bottom of the glass vial.Terminated
D-1147-201402-10-201403-12-2014115,500 VialsBupivacaine HCl Inj. USP, 0.5% (5 mg/mL), 30 mL Single-dose Preservative Free Vial, Rx Only, Hospira, Inc., Lake Forest, IL 60045, NDC 0409-1162-02Presence of Particulate Matter: Confirmed customer report of visible particulate embedded in the glass vial.Terminated
D-395-201410-11-201301-08-201465109 vials0.5% Bupivacaine HCl and Epinephrine 1:200,000 Inj., 50 mL, Multiple-dose Fliptop Vial, Rx only, Hospira, Inc., Lake Forest, IL 60045. NDC #0409-9046-01.Lack of assurance of sterility; equipment failure led to potential breach in asceptic process.Terminated
D-66295-00109-05-201310-16-2013187,150 vials0.5% Bupivacaine HCl and Epinephrine 1:200,000 Inj., 10 mL, Single-Dose Vial, NDC 0409-9045-01, Hospira, Inc., Lake Forest, IL 60045Lack of Assurance of Sterility; potential for vial breakageTerminated
D-381-201407-12-201312-25-2013119,600 vials0.75% Bupivacaine HCl Injection, USP, 7.5 mg/mL, 30 mL, Single-dose, Hospira Inc., Lake Forest, IL 60045, NDC 0409-1165-02Presence of particulate matter: visible free floating and partially embedded particulate matter in the glass vials.Terminated
D-380-201407-12-201312-25-2013118,100 vials0.25% Bupivacaine HCl Injection, USP, 2.5 mg/mL, 30 mL, Single-dose, Hospira Inc., Lake Forest, IL 60045, NDC 0409-1159-02Presence of particulate matter: visible free floating and partially embedded particulate matter in the glass vials.Terminated

What is a Recall Enforcement Report?

A Recall Enforcement Report is an official publication by the FDA that documents all classified drug recalls.

When a company initiates a product removal or correction, the FDA evaluates whether the action meets the criteria for a recall. If it does, the FDA assesses the level of public health risk and assigns a recall classification (Class I, II, or III). Once classified, the recall is published in the Enforcement Report, which includes details such as the product name, affected lot numbers, reason for recall, and scope of distribution.

The Enforcement Report ensures transparency and allows the public and healthcare professionals to stay informed about products that may present a health or safety concern.

Understanding Recall Reports

The recall information provided on this website is sourced directly from official U.S. Food and Drug Administration (FDA) data. It is important to understand that most product recalls are limited in scope and typically involve only specific lots or batches of a product that have been identified as potentially defective or non-compliant with regulatory standards.

Recalls may be initiated voluntarily by the manufacturer or distributor, or they may be mandated by the FDA when a product is found to pose a health risk. A recall does not necessarily mean that all units of a product are unsafe.

If you have concerns about the safety of a medication or healthcare product you are using, it is strongly recommended that you verify the product’s lot number and consult your pharmacist or healthcare provider to determine whether your specific product is affected by the recall.